Last reviewed · How we verify
regular human insulin
At a glance
| Generic name | regular human insulin |
|---|---|
| Also known as | Humulin R, RHI, Humulin R (100 U/mL), insulin, Novolin R Novonordisk |
| Sponsor | Halozyme Therapeutics |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effects of Diabetic Educational Intervention and Dietary Supplements on Blood Glucose, Lipid Profile Levels, Body Mass Index, and Pain Management Among Adult Individuals With Painful Diabetic Peripheral Neuropathy. (NA)
- Polycystic Ovary Syndrome in Type 1 Diabetes
- Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes (PHASE2)
- Safety and Feasibility of Intranasal Insulin in Patients With Spinal Cord Injury (PHASE1)
- Effect of Topical Insulin on Healing Rate of Pemphigus Lesions (PHASE2)
- Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals. (NA)
- Reprometabolic Syndrome Mediates Subfertility in Obesity (NA)
- Relative Desirability of Metformin vs. Birth Control Pill in Treating PCOS in Women of Later Reproductive Age (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- regular human insulin CI brief — competitive landscape report
- regular human insulin updates RSS · CI watch RSS
- Halozyme Therapeutics portfolio CI